Epidermal growth factor cancer vaccine (Bioven)

表皮生长因子癌症疫苗

Report date: 2026/04/22 20:01:10

Base Information

Drug NameEpidermal growth factor cancer vaccine (Bioven)
Drug Alias NamehrEGF-rP64k- Montanide ISA 51 VGrEGF-P64K/Montanide ISA 51 vaccineEGF-P64K cancer vaccineEGF cancer vaccineCimaVax EGF +[11] 
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Purpura, Thrombocytopenic, IdiopathicPulmonary Disease, Chronic Obstructive +[9] 
Global Approved IndicationsProstatic NeoplasmsCarcinoma, Non-Small-Cell LungStomach Neoplasms +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCuba
Original Approved Date2008/06/01
Country/TerritoryUnited StatesUkraineCuba +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCenter Of Molecular Immunology
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer InstituteBiopharma Plasma LLC
Inactive CompaniesBioven Sdn Bhd
Active IndicationsPurpura, Thrombocytopenic, IdiopathicPulmonary Disease, Chronic ObstructiveProstatic Neoplasms +[8] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeJ07X
Related LinksWikipedia